Literature DB >> 15334868

Incidence and management of hot flashes in prostate cancer.

Anna-Clara Spetz1, Eva-Lena Zetterlund, Eberhard Varenhorst, Mats Hammar.   

Abstract

Hot flashes are as common in men who have been castrated due to prostate cancer as hot flashes are in women after menopause. The symptom can cause significant discomfort for a considerable length of time. The hot flashes are most likely caused by a reduction in sex-hormone levels, which, in turn, causes an instability in the hypothalamic thermoregulatory center. Calcitonin gene-related peptide is involved in menopausal hot flashes in women and possibly also in castrated men. The mainstays of treatment for castrated men with hot flashes remain estrogens, progesterone, and cyproterone acetate, each of which has different side effects. Other treatments for hot flashes include clonidine and antidepressants and, according to one uncontrolled study, electrostimulated acupuncture. Nonetheless, there is a need for more effective and less toxic treatments. In this review, we will discuss the prevalence, duration, distress, physiology, and treatment options of hot flashes in men subjected to castration therapy due to prostate cancer.

Entities:  

Mesh:

Year:  2003        PMID: 15334868

Source DB:  PubMed          Journal:  J Support Oncol        ISSN: 1544-6794


  7 in total

1.  A Comprehensive Method To Quantify Adaptations by Male and Female Mice With Hot Flashes Induced by the Neurokinin B Receptor Agonist Senktide.

Authors:  Ashley A Krull; Sarah A Larsen; Donald K Clifton; Genevieve Neal-Perry; Robert A Steiner
Journal:  Endocrinology       Date:  2017-10-01       Impact factor: 4.736

2.  Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer.

Authors:  Peter Chang; Konrad M Szymanski; Rodney L Dunn; Jonathan J Chipman; Mark S Litwin; Paul L Nguyen; Christopher J Sweeney; Robert Cook; Andrew A Wagner; William C DeWolf; Glenn J Bubley; Renee Funches; Joseph A Aronovitz; John T Wei; Martin G Sanda
Journal:  J Urol       Date:  2011-07-23       Impact factor: 7.450

Review 3.  Management of complications of androgen deprivation therapy in the older man.

Authors:  Supriya G Mohile; Karen Mustian; Kathryn Bylow; William Hall; William Dale
Journal:  Crit Rev Oncol Hematol       Date:  2008-10-25       Impact factor: 6.312

Review 4.  Risk factors, pathophysiology, and treatment of hot flashes in cancer.

Authors:  William I Fisher; Aimee K Johnson; Gary R Elkins; Julie L Otte; Debra S Burns; Menggang Yu; Janet S Carpenter
Journal:  CA Cancer J Clin       Date:  2013-01-25       Impact factor: 508.702

5.  A randomised controlled trial of a brief cognitive behavioural intervention for men who have hot flushes following prostate cancer treatment (MANCAN).

Authors:  Evgenia Stefanopoulou; Omar Yousaf; Elizabeth A Grunfeld; Myra S Hunter
Journal:  Psychooncology       Date:  2015-03-09       Impact factor: 3.894

6.  The gender difference of snore distribution and increased tendency to snore in women with menopausal syndrome: a general population study.

Authors:  Li-Pang Chuang; Shih-Wei Lin; Li-Ang Lee; Hsueh-Yu Li; Chih-Hao Chang; Kuo-Chin Kao; Li-Fu Li; Chung-Chi Huang; Cheng-Ta Yang; Ning-Hung Chen
Journal:  Sleep Breath       Date:  2016-12-23       Impact factor: 2.816

7.  Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management.

Authors:  Petros Sountoulides; Thomas Rountos
Journal:  ISRN Urol       Date:  2013-07-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.